Claim 2, line 2, change "characterized in that it has" to --wherein the nucleic acids exhibits--;

Claim 3, line 1, change "sequence SEQ ID NO:1," to --the nucleic acids--;

Claim 3, line 11, change "the fragments of" to --wherein the fragments comprise--;

Claim 4, lines 1 and 2, change "Fragment according to Claim 3, characterized in that it is" to --A fragment according to Claim 3,--;

Claim 4, line 6, change "in that it" to --wherein the selected sequence--;

Claim 5, lines 1 and 2, change "Fragment according to Claim 3, characterized in that it is" to --A fragment according to Claim 3,--;

Claim 5, line 7 change "in that it is" to --wherein the selected sequence--;

Claim 6, line 1, change "Pairs" to ---A pair--;

Claim 7, line 1, change "Variant" to --A variant--;

Claim 8, line 1, change "Plasmid," to -- A plasmid--;

Claim 9, line 1, change "Plasmid" to --A plasmid--;

Claim 10, line 1, change "Diagnostic" to --A diagnostic--;

Claim 10, line 4, insert "and" before "the";

Claim 10, lines 6 and 7, delete ", optionally labelled with an appropriate marker";

Claim 11, line 1, change "Method" to --A method--;

Claim 12, line 1, change "Method" to --The method--;

Claim 13, line 1, change "Method" to --The method--;

Claim 13, lines 3, delete "according to Claim 6" and add:

--selected from the group consisting of:

pair A: primers SEQ ID NO:111 and SEQ ID NO:112;

pair B: primers SEQ ID NO:105 and SEQ ID NO:106;

pair C: one of the sequences SEQ ID NO:2-44, 105, 106, 107, 109, 111 or 112 and one of the sequences SEQ ID NO:45-80 108 or 110;

pair D: primer SEQ ID NO:107 and primer SEQ ID NO:109;

paid E: two primers selected from the sequences SEQ ID NO:2-44, 105, 106, 107, 109, 111 or 112; and

pair F: two primers selected from the sequences SEQ ID NO:45-80, 108 or 110.--

Claim 14, line 1, change "Method" to --A method--;

Claim 15, please cancel the entire claim;

Claim 16, line 1, change "Method" to --A method--;

Claim 16, lines 5 and 6, please delete "optionally labeled";

Claim 17, line 1, change "Products" to --A product--;

Claim 17, line 2, change "they are" to --it is--;

Claim 18, line 1, change "Protein" to --A protein--;

Claim 19, line 1, change "Protein or peptide, characterized in that it is" to --A protein or peptide,--;

Claim 19, line 3, delete the phrase, "in that it is";

Claim 20, line 1, change "Immunogenic compositions" to --An immunogenic composition--

Claim 20, lines 3 and 4, delete "and/or one of the peptides or proteins according to Claim 18 or Claim 19";

Claim 21, line 1, change "Antibodies" to --An antibody--;

Claim 21, lines 2 and 3, change "any one of Claims 17 to 20" to --Claim 17--;

Claim 22, please delete in its entirety;

Claim 23, please delete in its entirety;

Please add the following new claims, 24-37:

24. A method of *in vitro* screening diagnosis of infection of an individual with an erythrovirus comprising detecting hybridization of the individual's nucleic acid with a nucleic acid according to Claim 1.

25. The method of claim 24 comprising gene amplification.

26. The method of claim 16 wherein the probe is labeled.

27. The method of claim 16 wherein the nucleic acid of the virus to be typed is labeled.

28. An immunogenic composition comprising one or more of the proteins of claim 18.

29. An immunogenic composition comprising one or more of the peptides or proteins of claim 19.

30. An antibody directed against one or more of the proteins of claim 18.

31. An antibody directed against one or more of the proteins of claim 19.

32. A method for the immunological *in vitro* screening diagnosis of infection of an individual with an erythrovirus comprising detecting anti-erythrovirus V9 antibodies by contacting a biological sample with a peptide according to claim 17 and detecting the association of such a peptide with antibodies contained in the biological sample by an appropriate means.

33. The method of claim 32 wherein the appropriate detection means is selected from the group consisting of EIA, ELISA, RIA, and fluorescence.

34. A method for the immunological *in vitro* screening diagnosis of infection of an individual with an erythrovirus comprising detecting erythrovirus V9 viral proteins by contacting a biological sample with an antibody according to claim 21 and detecting the association of such an antibody with erythrovirus V9 viral proteins contained in the biological sample by an appropriate means.

35. The method of claim 34 wherein the appropriate detection means is selected from the group consisting of EIA, ELISA, RIA, and fluorescence.